{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:51:05Z","timestamp":1790139065100,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s10067-016-3506-4","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T21:41:08Z","timestamp":1481924468000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study"],"prefix":"10.1007","volume":"36","author":[{"given":"Claudia","family":"Fabiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Vannozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bacherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"3506_CR1","first-page":"S112","volume":"32","author":"G Hatemi","year":"2014","unstructured":"Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2014) Beh\u00e7et\u2019s syndrome: a critical digest of the 2013\u20132014 literature. Clin Exp Rheumatol 32:S112\u2013S122","journal-title":"Clin Exp Rheumatol"},{"key":"3506_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol 138:373\u2013380. doi: 10.1016\/j.ajo.2004.03.022","journal-title":"Am J Ophthalmol"},{"key":"3506_CR3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60\u201376","journal-title":"Medicine (Baltimore)"},{"key":"3506_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/09273948.2011.649153","volume":"20","author":"D Wakefield","year":"2012","unstructured":"Wakefield D, Cunningham ET Jr, Tugal-Tutkun I, Khairallah M, Ohno S, Zierhut M (2012) Controversies in Beh\u00e7et disease. Ocul Immunol Inflamm 20:6\u201311. doi: 10.3109\/09273948.2011.649153","journal-title":"Ocul Immunol Inflamm"},{"key":"3506_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P et al (2007) Epidemiology and clinical course of Beh\u00e7et\u2019s disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheumn 57:171\u2013178. doi: 10.1002\/art.22500","journal-title":"Arthritis Rheumn"},{"key":"3506_CR6","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2008) EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67:1656\u20131662. doi: 10.1136\/ard.2007.080432","journal-title":"Ann Rheum Dis"},{"key":"3506_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/ICU.0000000000000210","volume":"26","author":"C Fabiani","year":"2015","unstructured":"Fabiani C, Ali\u00f3 JL (2015) Local (topical and intraocular) therapy for ocular Adamantiades-Beh\u00e7et\u2019s disease. Curr Opin Ophthalmol 26:546\u2013552. doi: 10.1097\/ICU.0000000000000210","journal-title":"Curr Opin Ophthalmol"},{"key":"3506_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/BOR.0000000000000231","volume":"28","author":"Y Ozguler","year":"2016","unstructured":"Ozguler Y, Hatemi G (2016) Management of Beh\u00e7et\u2019s syndrome. Curr Opin Rheumatol 28:45\u201350. doi: 10.1097\/BOR.0000000000000231","journal-title":"Curr Opin Rheumatol"},{"key":"3506_CR9","first-page":"171","volume":"18","author":"A Vitale","year":"2016","unstructured":"Vitale A, Rigante D, Lopalco G, Selmi C, Galeazzi M, Iannone F et al (2016) Interleukin-1 inhibition in Beh\u00e7et\u2019s disease. Isr Med Assoc J 18:171\u2013176","journal-title":"Isr Med Assoc J"},{"key":"3506_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A et al (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis 71:563\u2013566. doi: 10.1136\/annrheumdis-2011-155143","journal-title":"Ann Rheum Dis"},{"key":"3506_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09273948.2015.1092558","volume":"30","author":"I Tugal-Tutkun","year":"2016","unstructured":"Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, \u00d6zyazgan Y et al (2016) Safety and efficacy of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm 30:1\u20139. doi: 10.3109\/09273948.2015.1092558","journal-title":"Ocul Immunol Inflamm"},{"key":"3506_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.09.017","author":"JE Knickelbein","year":"2016","unstructured":"Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D et al (2016) Gevokizumab in the treatment of autoimmune, non-necrotizing, anterior scleritis: results of a phase I\/II clinical trial. Am J Ophthalmol. doi: 10.1016\/j.ajo.2016.09.017","journal-title":"Am J Ophthalmol"},{"key":"3506_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R et al (2015) Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol 34:1293\u20131301. doi: 10.1007\/s10067-013-2443-8","journal-title":"Clin Rheumatol"},{"key":"3506_CR14","first-page":"152","volume":"31","author":"G Emmi","year":"2013","unstructured":"Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D et al (2013) Anakinra for resistant Beh\u00e7et uveitis: why not? Clin Exp Rheumatol 31:152\u2013153","journal-title":"Clin Exp Rheumatol"},{"key":"3506_CR15","first-page":"S171","volume":"32","author":"F Caso","year":"2014","unstructured":"Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) Efficacy of anakinra in refractory Beh\u00e7et\u2019s disease sacroiliitis. Clin Exp Rheumatol 32:S171","journal-title":"Clin Exp Rheumatol"},{"key":"3506_CR16","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet\u2019s syndrome with refractory eye disease. Ann Rheum Dis 71:1589\u20131591. doi: 10.1136\/annrheumdis-2012-201383","journal-title":"Ann Rheum Dis"},{"key":"3506_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology 228:211\u2013214. doi: 10.1159\/000358125","journal-title":"Dermatology"},{"key":"3506_CR18","first-page":"S115","volume":"30","author":"L Cantarini","year":"2012","unstructured":"Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 30:S115","journal-title":"Clin Exp Rheumatol"},{"key":"3506_CR19","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","unstructured":"Criteria for diagnosis of Beh\u00e7et\u2019s disease (1990) International study group for Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"3506_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD) (2014) The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338\u2013347. doi: 10.1111\/jdv.12107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3506_CR21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10067-006-0484-y","volume":"26","author":"FS Neves","year":"2007","unstructured":"Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gon\u00e7alves CR (2007) Cross-cultural adaptation of the Beh\u00e7et\u2019s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 26:1263\u20131267. doi: 10.1007\/s10067-006-0484-y","journal-title":"Clin Rheumatol"},{"key":"3506_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00281-015-0502-8","volume":"37","author":"A G\u00fcl","year":"2015","unstructured":"G\u00fcl A (2015) Pathogenesis of Beh\u00e7et\u2019s disease: autoinflammatory features and beyond. Semin Immunopathol 37:413\u2013418. doi: 10.1007\/s00281-015-0502-8","journal-title":"Semin Immunopathol"},{"key":"3506_CR23","first-page":"1544","volume":"20","author":"JL Mege","year":"1993","unstructured":"Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H et al (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544\u20131549","journal-title":"J Rheumatol"},{"key":"3506_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/eji.201343353","volume":"44","author":"M Castrichini","year":"2014","unstructured":"Castrichini M, Lazzerini PE, Gamberucci A, Capecchi PL, Franceschini R, Natale M et al (2014) The purinergic P2\u00d77 receptor is expressed on monocytes in Beh\u00e7et\u2019s disease and is modulated by TNF-\u03b1. Eur J Immunol 44:227\u2013238. doi: 10.1002\/eji.201343353","journal-title":"Eur J Immunol"},{"key":"3506_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1167\/iovs.12-11047","volume":"54","author":"L Liang","year":"2013","unstructured":"Liang L, Tan X, Zhou Q, Zhu Y, Tian Y, Yu H et al (2013) IL-1\u03b2 triggered by peptidoglycan and lipopolysaccharide through TLR2\/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Beh\u00e7et\u2019s disease. Invest Ophthalmol Vis Scib 54:402\u2013414. doi: 10.1167\/iovs.12-11047","journal-title":"Invest Ophthalmol Vis Scib"},{"key":"3506_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol 7:380. doi: 10.3389\/fphar.2016.00380","journal-title":"Front Pharmacol"},{"key":"3506_CR27","doi-asserted-by":"publisher","first-page":"107421","DOI":"10.1155\/2014\/107421","volume":"2014","author":"F Caso","year":"2014","unstructured":"Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V et al (2014) Biological treatments in Beh\u00e7et\u2019s disease: beyond anti-TNF therapy. Mediat Inflamm 2014:107421. doi: 10.1155\/2014\/107421","journal-title":"Mediat Inflamm"},{"key":"3506_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/rheumatology\/kev197","volume":"54","author":"I Pagnini","year":"2015","unstructured":"Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R (2015) Successful treatment with canakinumab of a paediatric patient with resistant Beh\u00e7et\u2019s disease. Rheumatology (Oxford) 54:1327\u20131328. doi: 10.1093\/rheumatology\/kev197","journal-title":"Rheumatology (Oxford)"},{"key":"3506_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease. Autoimmun Rev 14:1\u20139. doi: 10.1016\/j.autrev.2014.08.008","journal-title":"Autoimmun Rev"},{"key":"3506_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","volume":"29","author":"Y Bilginer","year":"2010","unstructured":"Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Beh\u00e7et\u2019s disease. Clin Rheumatol 29:209\u2013210. doi: 10.1007\/s10067-009-1279-8","journal-title":"Clin Rheumatol"},{"key":"3506_CR31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"C Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Beh\u00e7et disease responsive to anakinra. Ann Intern Med 149:284\u2013286","journal-title":"Ann Intern Med"},{"key":"3506_CR32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O et al (2016) Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study. Clin Rheumatol 35:1281\u20131286. doi: 10.1007\/s10067-015-3004-0","journal-title":"Clin Rheumatol"},{"key":"3506_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4049\/jimmunol.1502080","volume":"196","author":"CK Wan","year":"2016","unstructured":"Wan CK, He C, Sun L, Egwuagu CE, Leonard WJ (2016) Cutting edge: IL-1 receptor signaling is critical for the development of autoimmune uveitis. J Immunol 196:543\u2013546. doi: 10.4049\/jimmunol.1502080","journal-title":"J Immunol"},{"key":"3506_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"K Takase","year":"2011","unstructured":"Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis. Rheumatol Int 31:243\u2013245. doi: 10.1007\/s00296-009-1178-y","journal-title":"Rheumatol Int"},{"key":"3506_CR35","first-page":"S54","volume":"29","author":"I Olivieri","year":"2011","unstructured":"Olivieri I, Leccese P, D\u2019Angelo S, Padula A, Nigro A, Palazzi C et al (2011) Efficacy of adalimumab in patients with Beh\u00e7et\u2019s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29:S54\u2013S57","journal-title":"Clin Exp Rheumatol"},{"key":"3506_CR36","first-page":"S79","volume":"30","author":"H Yazici","year":"2012","unstructured":"Yazici H, Hatemi G (2012) Empiricism in managing Beh\u00e7et\u2019s syndrome. Clin Exp Rheumatol 30:S79","journal-title":"Clin Exp Rheumatol"},{"key":"3506_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3417-4","author":"A Vitale","year":"2016","unstructured":"Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C et al (2016) Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol [Epub ahead of print]. doi: 10.1007\/s10067-016-3417-4","journal-title":"Clin Rheumatol [Epub ahead of print]"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3506-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:04:43Z","timestamp":1498356283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3506-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3506"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3506-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,16]]}}}